Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
On Oct. 16, 2026, IART is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5172 stocks scored that day.
Integra Lifesciences Holdings Corp is a small-cap company with a market capitalization of $1.03B. It ranks number 35 by market capitalization among the 60 Surgical & Medical Instruments & Apparatus issuers in our coverage with a current forecast.
For IART, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 31.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 39.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, IART included.
Follow IART free90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Surgical & Medical Instruments & Apparatus peers listed below that report each metric.
| Metric | IART | Rank |
|---|---|---|
| Market Cap | $1.03B | 35/60 |
| P/B Ratio | 0.98x | 53/55 |
| EPS | $-0.43 | – |
| Book Value/Share | $13.42 | – |
| Revenue/Share | $21.19 | – |
| FCF/Share | $0.33 | – |
| Metric | IART | Rank |
|---|---|---|
| ROIC | 2.0% | 25/53 |
| Gross Margin | 52.5% | 42/53 |
| Operating Margin | 4.0% | 23/54 |
| EBT Margin | -0.0% | 27/54 |
| Tax Rate | -3946.4% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
| Metric | IART | Rank |
|---|---|---|
| Current Ratio | 3.60x | 31/59 |
| Quick Ratio | 2.11x | 33/55 |
| D/E Ratio | 2.42x | 7/56 |
| Financial Leverage | 3.42x | 7/54 |
| Interest Coverage | 0.3x | 24/48 |
| Working Capital | $861M | 13/59 |
| Metric | IART | Rank |
|---|---|---|
| Operating Cash Flow | $85M | 22/55 |
| Free Cash Flow | $26M | 22/50 |
| Capital Spending | -$60M | 35/50 |
| OCF Growth YoY | 20.4% | 16/33 |
| FCF/Sales | 1.6% | 24/49 |
| CapEx/Sales | 3.6% | 26/49 |
| Metric | IART | Rank |
|---|---|---|
| Asset Turnover | 0.46x | 41/50 |
| Receivables Turnover | 6.2x | 31/51 |
| Inventory Turnover | 1.6x | 38/51 |
| Fixed Assets Turnover | 3.7x | 38/52 |
| Days Sales Outstanding | 59 days | 21/51 |
| Days Inventory | 229 days | 14/51 |
| Metric | IART | Rank |
|---|---|---|
| Total Revenue | $1.65B | 14/52 |
| Operating Income | $66M | 19/55 |
| R&D Expense | $95M | 19/53 |
| SG&A Expense | $689M | 14/53 |
| Cost of Goods Sold | $783M | 15/53 |
| Metric | IART | Rank |
|---|---|---|
| Shares Outstanding | 78M | – |
| Total Current Assets | $1.19B | 33.4% of assets |
| Cash & Short-term Investments | $214M | 6.0% of assets |
| Accounts Receivable | $267M | 7.5% of assets |
| Inventory | $492M | 13.8% of assets |
| Total Liabilities | $2.52B | 70.7% of assets |
Companies classified under the same SEC industry code as Integra Lifesciences Holdings Corp (Surgical & Medical Instruments & Apparatus): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| IART Integra Lifesciences Holdings Corp | ▶ | $1.03B |
| SYK Stryker Corp | ▼ | $113.02B |
| MMM 3m Co | ▶ | $84.97B |
| BSX Boston Scientific Corp | ▼ | $64.33B |
| BDX Becton Dickinson & Co | ▼ | $52.23B |
| MDLN Medline Inc. | ▶ | $47.28B |
| RMD Resmed Inc | ▼ | $34.47B |
| DXCM Dexcom Inc | ▼ | $32.47B |
| WST West Pharmaceutical Services Inc | ▼ | $27.03B |
| SOLV Solventum Corp | ▼ | $14.61B |
| BAX Baxter International Inc | ▼ | $13.07B |
| PEN Penumbra Inc | ▼ | $12.64B |
| GMED Globus Medical Inc | ▼ | $10.30B |
| PODD Insulet Corp | ▼ | $9.79B |
| GKOS Glaukos Corp | ▲ | $9.72B |
| TFX Teleflex Inc | ▼ | $5.53B |
| HAE Haemonetics Corp | ▶ | $5.38B |
| MMSI Merit Medical Systems Inc | ▼ | $5.33B |
| STVN Stevanato Group S.P.A. | ▲ | $5.16B |
| MMED Minimed Group, Inc. | ▲ | $4.92B |
| HTFL Heartflow, Inc. | ▲ | $4.20B |
| ICUI Icu Medical Inc/De | ▼ | $4.08B |
| IRTC Irhythm Holdings, Inc. | ▼ | $3.58B |
| PLSE Pulse Biosciences, Inc. | ▲ | $3.17B |
| ATRC Atricure, Inc. | ▲ | $2.85B |
| UFPT Ufp Technologies Inc | ▼ | $2.26B |
| INSP Inspire Medical Systems, Inc. | ▲ | $1.99B |
| LMAT Lemaitre Vascular Inc | ▶ | $1.85B |
| NVCR Novocure Ltd | ▲ | $1.64B |
| KMTS Kestra Medical Technologies, Ltd. | ▲ | $1.62B |
| ATEC Alphatec Holdings, Inc. | ▲ | $1.62B |
| TNDM Tandem Diabetes Care Inc | ▲ | $1.13B |
| IRMD Iradimed Corp | ▶ | $1.13B |
| DRTS Alpha Tau Medical Ltd. | ▶ | $1.08B |
| AORT Artivion, Inc. | ▶ | $1.06B |
| PRCT Procept Biorobotics Corp | ▲ | $1.01B |
| BVS Bioventus Inc. | ▶ | $908M |
| SIBN Si-Bone, Inc. | ▶ | $882M |
| BBNX Beta Bionics, Inc. | ▲ | $863M |
| SGP Spyglass Pharma, Inc. | ▶ | $803M |
| MDXG Mimedx Group, Inc. | ▲ | $646M |
| KIDS Orthopediatrics Corp | ▶ | $573M |
| SSII Ss Innovations International, Inc. | ▲ | $517M |
| TCMD Tactile Systems Technology Inc | ▼ | $510M |
| DCTH Delcath Systems, Inc. | ▲ | $497M |
| ANGO Angiodynamics Inc | ▲ | $473M |
| SGHT Sight Sciences, Inc. | ▲ | $456M |
| BWAY Brainsway Ltd. | ▶ | $448M |
| CERS Cerus Corp | ▶ | $439M |
| NPCE Neuropace Inc | ▶ | $420M |
| RCEL Avita Medical, Inc. | ▲ | $403M |
| OFIX Orthofix Medical Inc. | ▼ | $382M |
| CARL Carlsmed, Inc. | ▲ | $366M |
| EMBC Embecta Corp. | ▶ | $355M |
| OBIO Orchestra Biomed Holdings, Inc. | ▲ | $328M |
| CLPT Clearpoint Neuro, Inc. | ▲ | $277M |
| MOBI Mobia Medical, Inc. | ▼ | $269M |
| ANIK Anika Therapeutics, Inc. | ▶ | $267M |
| TMCI Treace Medical Concepts, Inc. | ▲ | $252M |
| OSUR Orasure Technologies Inc | ▲ | $249M |
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Integra Lifesciences Holdings Corp (NASDAQ:IART) cut its 2026 revenue and adjusted earnings guidance after July flooding disrupted operations in Cincinnati, despite expectations for strong cash ...
Integra LifeSciences Holdings Corp. ( IART ), a global medical technology company, announced the pricing of $450 million aggregate principal amount of 9.5% senior secured notes due 2033.
On Oct. 16, 2026, IART is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5172 stocks scored that day.
For IART, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 31.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 39.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Integra Lifesciences Holdings Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
60 issuers in our coverage, IART included, share the SEC industry code Surgical & Medical Instruments & Apparatus. The largest are: Stryker Corp (SYK), 3m Co (MMM), Boston Scientific Corp (BSX), Becton Dickinson & Co (BDX), Medline Inc. (MDLN), Resmed Inc (RMD).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.